Pfizer Says EC Approves Vizimpro for Non-Small Cell Lung Cancer

Date : 03/04/2019 @ 16h33
Source : Dow Jones News
Valeur : Pfizer, Inc. (PFE)
Cours : 41.47  -0.17 (-0.41%) @ 01h44
Pfizer Cours Graphique

Pfizer Says EC Approves Vizimpro for Non-Small Cell Lung Cancer

Pfizer (NYSE:PFE)
Graphique Historique de l'Action

2 Mois : De Mar 2019 à Mai 2019

Plus de graphiques de la Bourse Pfizer

By Michael Dabaie


Pfizer Inc. (PFE) said Wednesday the European Commission approved Vizimpro as monotherapy for the first-line treatment of lung cancer.

The EC approved Vizimpro for adult patients with locally advanced or metastatic non-small cell lung cancer with epidermal growth factor receptor-activating mutations. The EC's approval was supported by data from the Archer 1050 Phase 3 study. The primary endpoint was progression-free survival as determined by blinded Independent Radiologic Central review. A statistically significant improvement in PFS as determined by the IRC was demonstrated, the company said.

In 2012, Pfizer and SFJ Pharmaceuticals agreed to conduct the Archer 1050 study across multiple sites. SFJ Pharmaceuticals provided the funding and conducted the trial to generate the clinical data used to support this application. Pfizer retains all rights to commercialize Vizimpro globally.


Write to Michael Dabaie at


(END) Dow Jones Newswires

April 03, 2019 10:18 ET (14:18 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.
Dernières Valeurs Consultées
Société Gé..
CAC 40
Euro vs Do..
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.

Inscrivez-vous maintenant pour créer votre liste d'actions personnalisée, en streaming.

Les cours EURONEXT (CAC 40, etc. ) et FOREX (les devises) sont en direct si connecté.
NYSE, AMEX, et ASX sont en différé d'environ 20 minutes. Les autres cours sont en différé d'environ 15 minutes.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Conditions Générales

P: V:fr D:20190519 13:16:12